company background image
A217330 logo

Cytogen KOSDAQ:A217330 Stock Report

Last Price

₩14.75k

Market Cap

₩328.7b

7D

1.0%

1Y

-8.4%

Updated

26 Mar, 2024

Data

Company Financials

A217330 Stock Overview

Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea.

A217330 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Cytogen, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Cytogen
Historical stock prices
Current Share Price₩14,750.00
52 Week High₩20,200.00
52 Week Low₩10,100.00
Beta0.64
1 Month Change-1.67%
3 Month Change11.07%
1 Year Change-8.39%
3 Year Change-24.23%
5 Year Change256.85%
Change since IPO183.65%

Recent News & Updates

Recent updates

Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

Mar 23
Is Cytogen (KOSDAQ:217330) Weighed On By Its Debt Load?

What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

Jan 25
What You Need To Know About Cytogen, Inc.'s (KOSDAQ:217330) Investor Composition

Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

Dec 03
Is Cytogen (KOSDAQ:217330) Using Too Much Debt?

Shareholder Returns

A217330KR BiotechsKR Market
7D1.0%4.1%2.1%
1Y-8.4%20.9%13.4%

Return vs Industry: A217330 underperformed the KR Biotechs industry which returned 20.9% over the past year.

Return vs Market: A217330 underperformed the KR Market which returned 13.4% over the past year.

Price Volatility

Is A217330's price volatile compared to industry and market?
A217330 volatility
A217330 Average Weekly Movement8.9%
Biotechs Industry Average Movement7.9%
Market Average Movement5.2%
10% most volatile stocks in KR Market12.0%
10% least volatile stocks in KR Market2.4%

Stable Share Price: A217330's share price has been volatile over the past 3 months.

Volatility Over Time: A217330's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of KR stocks.

About the Company

FoundedEmployeesCEOWebsite
201045Byung-Hee Jeonhttps://www.cytogenlab.com

Cytogen, Inc., a biotechnology company, develops and sells CTC (circulating tumor cell) enrichment and downstream systems to treat cancer in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immune florescence staining systems; and cell image analyzers, which help capture and analyze multi-fluorescence images with multi-channel image sensors and cameras. It also provides time laps incubators, which help monitoring cell growth and capture cell images from the cell culture plates.

Cytogen, Inc. Fundamentals Summary

How do Cytogen's earnings and revenue compare to its market cap?
A217330 fundamental statistics
Market cap₩328.74b
Earnings (TTM)-₩16.40b
Revenue (TTM)₩2.84b

115.8x

P/S Ratio

-20.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
A217330 income statement (TTM)
Revenue₩2.84b
Cost of Revenue₩1.95b
Gross Profit₩890.94m
Other Expenses₩17.29b
Earnings-₩16.40b

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-735.88
Gross Margin31.39%
Net Profit Margin-577.81%
Debt/Equity Ratio96.3%

How did A217330 perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.